Neflamapimod induces vasodilation in resistance mesenteric arteries by inhibiting p38 MAPKα and downstream Hsp27 phosphorylation

Neflamapimod, a selective inhibitor of p38 mitogen activated protein kinase alpha (MAPKα), is under clinical investigation for its efficacy in Alzheimer’s disease (AD) and dementia with Lewy Bodies (DLB). Here, we investigated if neflamapimod-mediated acute inhibition of p38 MAPKα could induce vasod...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Ajay K., Zerin, Farzana, Menon, Sreelakshmi N., Tithi, Tanzia I., Nguyen, Khue P., Vo, Tran, Daniel, Morgan L., Hafez, Sherif, Alam, Md. Ashraful, Hasan, Raquibul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941071/
https://www.ncbi.nlm.nih.gov/pubmed/35318382
http://dx.doi.org/10.1038/s41598-022-08877-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941071/
https://www.ncbi.nlm.nih.gov/pubmed/35318382
http://dx.doi.org/10.1038/s41598-022-08877-8

Ejemplares similares